<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117386</url>
  </required_header>
  <id_info>
    <org_study_id>IRB NO. 405/62</org_study_id>
    <nct_id>NCT04117386</nct_id>
  </id_info>
  <brief_title>Prevalence of HPV-associated Eye Infection and Cytokine Levels in Tears From Patients Diagnosed With Pterygium</brief_title>
  <official_title>Prevalence of HPV-associated Eye Infection and Cytokine Levels in Tears From Patients Diagnosed With Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of HPV-associated eye infection and cytokine levels in tears from patients
      diagnosed with pterygium
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to evaluate the prevalence of HPV infection in primary and
      recurrent pterygium and the association of HPV types collecting from conjunctiva swab and
      urine. The second purpose is to compare a quantity of cytokines including IL-6, IL-18 and
      growth factor including VEGF found in tears of patients with primary and recurrent pterygium
      to participants with free of ocular disease Primary hypothesis

      - The prevalence of HPV infection in primary pterygium is difference with prevalence in
      recurrent pterygium patients.

      Secondary hypothesis

        -  Ocular HPV infection has association with HPV genitalia infection.

        -  Tears cytokine and growth factor level (IL-6, IL-18 and VEGF) are higher in pterygium
           HPV infection than non-HPV infection and also more than normal population
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HPV prevalence</measure>
    <time_frame>1 hour per participants which is on a day for collecting sample</time_frame>
    <description>1. To compare HPV prevalence in subjects with primary pterygium and with recurrent pterygium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV autoinoculation</measure>
    <time_frame>1 hour per participants which is on a day for collecting sample</time_frame>
    <description>To assess whether HPV autoinoculation is present, we evaluate whether there is an association between HPV ocular infection and genital infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytokine IL-6, IL-18 and VEGF levels</measure>
    <time_frame>1 hour per participants which is on a day for collecting sample</time_frame>
    <description>To compare cytokine IL-6, IL-18 and VEGF levels among various subgroups, including recurrent pterygium subjects with HPV positive and HPV negative status, primary pterygium subjects with HPV positive and HPV negative, and subjects without ocular diseases</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">141</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>Primary pterygium group</arm_group_label>
    <description>Participants who was diagnosed with primary pterygium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary pterygium group</arm_group_label>
    <description>Participants who was diagnosed with secondary pterygium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy participants as control group</arm_group_label>
    <description>Participants who have no pterygium and other inflammation disease in eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)</intervention_name>
    <description>HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)</description>
    <arm_group_label>Healthy participants as control group</arm_group_label>
    <arm_group_label>Primary pterygium group</arm_group_label>
    <arm_group_label>Secondary pterygium group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bio-PlexÂ® 200 system (Bio- Rad, Hercules, CA)</intervention_name>
    <description>Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip</description>
    <arm_group_label>Healthy participants as control group</arm_group_label>
    <arm_group_label>Primary pterygium group</arm_group_label>
    <arm_group_label>Secondary pterygium group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population:Patients diagnosed with primary pterygium and recurrent pterygium Target
        Population: Patients diagnosed with primary pterygium at out-patient clinic, Department of
        Ophthalmology, King Chulalongkorn Memorial Hospital Control Population: participants
        without any ocular diseases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Participants as primary and secondary pterygium group

        Inclusion Criteria:

          -  Age above 18 years old

          -  presence of pterygium invading the cornea

        Exclusion Criteria:

          -  Other ocular inflammation that could affect the results of the study (such as
             conjunctivitis, keratitis, conjunctival tumor, etc) or would preclude the enrollment
             for safety reasons

        Participant without ocular disease Inclusion criteria

          -  Age above 18 years old Exclusion criteria

          -  Presence of any ocular inflammation diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ngamjit Kasetsuwan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of medicine, Chulalongkorn university</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Ngamjit Kasetsuwan</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>HPV infection</keyword>
  <keyword>Pterygium</keyword>
  <keyword>Cytokine</keyword>
  <keyword>VEGF</keyword>
  <keyword>auto-inoculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>If there is anybody contacting our team for data in the purpose of future research, we agree to share our data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after published</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

